- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.07. | Liminatus plans to invest up to $500 million in BNB coin | 4 | Investing.com | ||
| 28.07. | Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative | 2 | GlobeNewswire (USA) | ||
| 25.07. | Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | 218 | GlobeNewswire (Europe) | LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 24.07. | Liminatus Pharma stock soars after engaging Digital Offering for capital raise | 2 | Investing.com | ||
| 24.07. | Pre-market Movers: Sadot Group, Community Health Systems, Liminatus Pharma, MaxLinear, Incannex Healthcare | 689 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.10 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 25% at... ► Artikel lesen | |
| LIMINATUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.07. | Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy | 1 | GlobeNewswire (USA) | ||
| 22.07. | Liminatus gains amid review to consider digital assets for treasury management | 2 | Seeking Alpha | ||
| 22.07. | Liminatus Pharma explores digital assets for treasury management | 1 | Investing.com | ||
| 22.07. | Liminatus Pharma Inc.: Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy | 160 | GlobeNewswire (Europe) | LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 11.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.07. | Liminatus Pharma bildet Konsortium für Bauchspeicheldrüsenkrebs-Diagnosekit | 2 | Investing.com Deutsch | ||
| 03.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma files to sell 6.9M shares of common stock | 2 | Seeking Alpha | ||
| 24.06. | Liminatus Pharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 703 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 05.06. | Liminatus Pharma stock gains on regaining compliance with Nasdaq | 1 | Seeking Alpha | ||
| 05.06. | Liminatus Pharma-Aktien steigen nach Nasdaq-Compliance-Meldung | 5 | Investing.com Deutsch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TENAYA THERAPEUTICS | 1,130 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase... ► Artikel lesen | |
| QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
| IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| EVOTEC | 6,000 | +0,03 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
| RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| ADMA BIOLOGICS | 17,255 | -0,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
LIMINATUS PHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,81 % bei einem Aktienkurs von 2,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.